Actively Recruiting
Functional Pulmonary Capillary Surface Area in BPA for CTEPH
Led by Jewish General Hospital · Updated on 2025-09-23
40
Participants Needed
1
Research Sites
253 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic thromboembolic pulmonary hypertension \[CTEPH\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \[BPA\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \[FCSA\] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.
CONDITIONS
Official Title
Functional Pulmonary Capillary Surface Area in BPA for CTEPH
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
You will not qualify if you...
- Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
- Presence of patent foramen ovale
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
David Langleben
Montreal, Quebec, Canada, H3W 2C4
Actively Recruiting
Research Team
D
David Langleben, MD
CONTACT
L
Lyda Lesenko, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here